BCMA-CD19 cCAR T cells

BIOLOGICAL3 trials

Sponsors

iCell Gene Therapeutics

Conditions

Multiple Myeloma in RelapsePlasmacytoid; LymphomaRefractory Immune CytopeniaRefractory Multiple MyelomaRelapsed/Refractory, Systemic Lupus Erythematosus (SLE)

Phase 1

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

RecruitingNCT04162353

iCell Gene TherapeuticsMultiple Myeloma in Relapse, Plasmacytoid; Lymphoma, Refractory Multiple Myeloma

Start: 2019-07-01End: 2026-07-31Target: 12Updated: 2025-09-16

BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

iCell Gene TherapeuticsRelapsed/Refractory, Systemic Lupus Erythematosus (SLE)

Start: 2022-04-01End: 2025-04-30Target: 15Updated: 2022-07-26

BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases

RecruitingNCT06787989

iCell Gene TherapeuticsRefractory Immune Cytopenia

Start: 2024-08-31End: 2027-04-30Target: 20Updated: 2025-01-22